Pharmacokinetics of tenofovir during pregnancy and postpartum-Reference-Cited by-同舟云学术

Pharmacokinetics of tenofovir during pregnancy and postpartum

Published:2015-05-11 Issue:8 Volume:16 Page:502-511
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Med

Author:

Best BM¹,Burchett S²,Li H³,Stek A⁴,Hu C⁵,Wang J⁶,Hawkins E⁷,Byroads M⁸,Watts DH⁹,Smith E¹⁰,Fletcher CV¹¹,Capparelli EV¹,Mirochnick M¹²,

Affiliation:

1. School of Medicine-Rady Children's Hospital and Skaggs School of Pharmacy & Pharmaceutical Sciences; University of California San Diego; San Diego CA USA

2. Harvard Medical School; Children's Hospital Boston; Boston MA USA

3. Department of Preventive Medicine; Rush University Medical Center; Chicago IL USA

4. Department of Obstetrics and Gynecology; University of Southern California School of Medicine; Los Angeles CA USA

5. Division of Epidemiology and Biostatistics; University of Arizona Mel & Enid Zuckerman College of Public Health; Tucson AZ USA

6. Harvard School of Public Health; Center for Biostatistics in AIDS Research; Boston MA USA

7. Social and Scientific Systems; Silver Springs MD USA

8. Frontier Science & Technology Research Foundation; Amherst NY USA

9. Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Bethesda MD USA

10. National Institute of Allergy and Infectious Diseases (NIAID); Bethesda MD USA

11. College of Pharmacy; University of Nebraska Medical Center; Omaha NE USA

12. Boston University School of Medicine; Boston MA USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Reference16 articles.

1. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf

2. Pharmacokinetic optimization of antiretroviral therapy in pregnancy;Buckoreelall;Clin Pharmacokinet,2012

3. Impact of a tenofovir disoproxil fumarate plus ritonavir-boosted protease inhibitor-based regimen on renal function in HIV-infected individuals: a prospective, multicenter study;Cao;BMC Infect Dis,2013

4. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial;Rasmussen;PLoS ONE,2012

5. Sensitive assay for determining plasma tenofovir concentrations by LC/MS/MS;Delahunty;J Chromatogr B Analyt Technol Biomed Life Sci,2006

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In-utero exposure to tenofovir disoproxil fumarate pre-exposure prophylaxis and growth metrics in HIV unexposed breastfed infants in South Africa: a post hoc analysis of the CAP 016 PrEP in pregnancy RCT;Frontiers in Pediatrics;2024-08-09

2. Adherence and HIV Protection Thresholds for Emtricitabine and Tenofovir Disoproxil Fumarate Preexposure Prophylaxis among Cisgender Women: A Systematic Review;Current HIV/AIDS Reports;2024-08-09

3. Phosphaturia in HIV-Exposed Uninfected Neonates Associated with Maternal Use of Tenofovir Disoproxil Fumarate in Late Pregnancy;Journal of the Pediatric Infectious Diseases Society;2024-05-31

4. Establishing adherence–concentration–efficacy thresholds of TDF–FTC pre-exposure prophylaxis for HIV prevention in African women: a protocol for the Women TDF–FTC Benchmark Study;Frontiers in Reproductive Health;2024-05-27

5. Pharmacokinetic and toxicological considerations affecting antiretroviral drug dosing in pregnant women;Expert Opinion on Drug Metabolism & Toxicology;2024-05-14